Scientific Program

Wednesday, June 26 2019
8:15 am Welcome

Charles Swanton (London, UK)
Roman Thomas (Cologne, DE)
Reinhard Büttner (Cologne, DE)
Jürgen Wolf (Cologne, DE)

8:30 - 10:30 am Session I: Immune Checkpoint Inhibitors: Resistance and Combinations

Chairs: Kwok Wong (Boston, US), Jürgen Wolf (Köln, DE)

8:30 - 9:00 am ICI combinations: effective alternatives to chemotherapy?

Solange Peters (Lausanne, CH)

9:00 - 9:30 am Patients relapsing after ICI 1st line therapy: new therapeutic strategies

Martin Reck (Grosshansdorf, DE)

9:30 - 10:00 am Mechanisms of response to CTLA4 and PD1 antibody therapy

Sergio Quezada (London, UK)

10:00 - 10:30 am Perspective on clinical management of challenging patients: illustration by a real-life case

Martin Sebastian (Frankfurt/M, DE), Kwok Wong (Boston, US)

10:30 am Coffee Break
11:00 - 1:00 pm Session II: Immunotherapy: Beyond PD-1

Chairs: Martin Sebastian (Frankfurt, DE), Solange Peters (Lausanne, CH)

11:00 - 11:30 am Lung cancer evolution and Immune Evasion

Charles Swanton (London, UK)

11:30 - 12:00 pm Targeting the tumor microenvironment to improve anti-tumor immunity

Michael Hölzel (Bonn, DE)

12:00 - 12:30 pm Mechanistically informed combination immunotherapy

Kwok Wong (Boston, US)

12:30 - 1:00 pm Individualized tumor vaccines

Ugur Sahin (Mainz, DE)

1:00 pm Lunch
2:00 - 4:00 pm Session III: News from the Kinome (I)

Chairs: Wilfried Eberhardt (Essen, DE), Ben Solomon (Melbourne, AUS)

2:00 - 2:30 pm EGFR mutant lung cancer: treatment strategies after failure of 3rd gen. EGFR-TKIs

Lecia Sequist (Boston, US)

2:30 - 3:00 pm KRAS mutant lung cancer: light at the end of the tunnel?

Pasi Jänne (Boston, US)

3:00 - 3:30 pm ALK positive lung cancer: choosing the optimal sequence

Alice Shaw (Boston, US)

3:30 - 4:00 pm Perspective on clinical management of challenging patients: illustration by a real-life case

Oliver Gautschi (Lucerne, CH), Egbert Smit (Amsterdam, NL)

4:00 pm Coffee Break
4:30 - 6:30 pm Session IV: Clonal Evolution and Genetic Heterogeneity

Chairs: Charles Swanton (London, UK), Frank Griesinger (Oldenburg, DE)

4:30 - 5:00 pm Clinical implications of tumor heterogeneity

Mariam Hanjani (London, UK)

5:00 - 5:30 pm Evolutionary dynamics and drug resistance

Martin Peifer (Cologne, DE)

5:30 - 6:00 pm Circulating tumor DNA

Maximilian Diehn (Stanford, US)

6:00 - 6:30 pm Molecular Determinants of Lung Cancer Initiation and Growth

Monte Winslow (Stanford, US)

6:30 - 7:30 pm Keynote Lecture

Tony Mok (Hong Kong, CHN)

8:00 pm Social event (SkyKöln) including scientific summary of the day (talk J. Wolf)
Thursday, June 27 2019
8:30 - 10:30 am Session V: News from the Kinome (II)

Chairs: Reinhard Büttner (Köln, DE), Pasi Jänne (Boston, US)

8:30 - 9:00 am Upcoming new targets

Ben Solomon (Melbourne, AUS)

9:00 - 9:30 am Acquired resistance in lung cancers bearing kinase gene rearrangements

Robert Doebele (Colorado, US)

9:30 - 10:00 am The next next generation of kinase inhibitors

Daniel Rauh (Dortmund, DE)

10:00 - 10:30 am Immunotherapy in oncogene-addicted lung cancer

Rafael Rosell (Barcelona, ES)

10:30 am Coffee Break
11:00 - 1:00 pm Session VI: Small Cell Lung Cancer

Chairs: Michael Thomas (Heidelberg, DE), Roman Thomas (Köln, DE)

11:00 - 11:05 am Cheque presentation
11:05 - 11:30 am Circulating tumor cells in SCLC: opportunities for new therapeutic strategies

Caroline Dive (Manchester, UK)

11:30 - 12:00 pm Acquired drug resistance in SCLC

Julie George (Cologne, DE)

12:00 - 12:30 pm Transcription factor alterations in SCLC

Anton Berns (Amsterdam, NL)

12:30 - 1:00 pm Kinase signaling networks in SCLC

Julien Sage (Stanford, US)

1:00 pm Concluding Remarks

Charles Swanton (London, UK)
Roman Thomas (Cologne, DE)
Reinhard Büttner (Cologne, DE)
Jürgen Wolf (Cologne, DE)

1:15 pm Lunch